13F Holdings
中文EN

VCNX VACCINEX, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1205922 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.4%
TTM net income YoY8.0%
TTM EPS YoY79.7%
Revenue 3-yr CAGR-12.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,117.3%
Net margin-3,100.5%
FCF margin-2,696.8%
EBITDA margin-3,101.8%

Returns

ROE—
ROA-598.5%
ROIC (approx.)—
Asset turnover0.19x

Leverage & solvency

Liabilities / assets195.8%
Debt / equity—
Current ratio0.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-78.6%
Payout ratio—
Capex / revenue3.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue$601,000$570,000$275,000$900,000$625,000
Cost of revenue————$2,000
Gross profit————$623,000
R&D expense$12.54M$16.57M$13.98M$17.16M$21.55M
SG&A expense$6.79M$6.88M$6.20M$6.23M$7.41M
Operating income-$18.73M-$22.89M-$19.91M-$22.49M-$28.33M
Interest expense$2,000$1,000$2,000$809,000$489,000
Pretax income-$18.63M-$20.25M-$19.82M-$22.38M-$28.85M
Income tax$0$0$0$0$0
Net income-$18.63M-$20.25M-$19.82M-$22.38M-$28.85M
EBITDA-$18.64M-$22.77M-$19.70M-$22.32M-$28.02M
EPS (basic)-8.88-43.68-98.05-0.78-1.54
EPS (diluted)-8.88-43.68-98.05-0.78-1.54
Weighted avg. shares (diluted)2.10M463,653202,08228.85M18.79M
Balance sheet
Cash & equivalents$1.11M$1.53M$6.39M$8.59M$10.60M
Receivables$838,000$961,000$175,000—$157,000
Current assets$2.53M$3.35M$7.48M$9.40M$11.29M
PP&E, net$65,000$136,000$189,000$297,000$416,000
Total assets$2.60M$3.63M$7.98M$9.84M$11.70M
Current liabilities$5.08M$5.92M$2.54M$2.26M$13.18M
Short-term debt$25,000$75,000$74,000$74,000—
Long-term debt$0$26,000$101,000$175,000$1.13M
Total debt$25,000$101,000$175,000$249,000$1.13M
Total liabilities$5.08M$5.94M$2.78M$2.43M$14.31M
Shareholders' equity-$2.49M-$2.31M$5.19M$7.41M-$26.57M
Net debt-$1.08M-$1.43M-$6.22M-$8.34M-$9.46M
Shares outstanding2.68M892,617237,52730.80M22.39M
Cash flow statement
Operating cash flow-$16.19M-$21.38M-$19.07M-$25.30M-$28.65M
Capital expenditure$22,000$67,000$99,000$32,000$290,000
Free cash flow-$16.21M-$21.45M-$19.17M-$25.33M-$28.94M
Investing cash flow-$22,000-$67,000-$99,000-$32,000-$290,000
Financing cash flow$15.78M$16.59M$16.98M$23.32M$36.76M
Depreciation & amortization$94,000$119,000$207,000$169,000$307,000
Stock-based compensation$341,000$474,000$545,000$541,000$732,000

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.